Some dosage forms listed on this page may not apply specifically to the brand name Pluvicto. Applies to lutetium lu 177 vipivotide tetraxetan: intravenous solution. Serious side effects of Pluvicto. Along with its needed effects, lutetium lu 177 vipivotide tetraxetan (the active ingredient contained in Pluvicto) may cause some unwanted effects
The use of Pluvicto may raise some equity and access challenges due to limitations in the capacity to supply the infrastructure needed to test for PSMA positivity (e.g, PSMA PET-CT scans), as well as the manufacture and delivery of Pluvicto itself.
Pluvicto is a targeted radioactive medicine that works by targeting the PSMA protein on prostate cancer cells.
Pluvicto is being reviewed by the Canadian Agency for Drugs and Technology in Health with Feb. 16, 2024, the deadline for stakeholder feedback. CADTH will recommend whether the drug should be publicly funded. Health Canada has approved Pluvicto and it can now be marketed.
Pluvicto binds to a protein called PSMA, which is found on some prostate cancer cells. It gives off radiation that may kill the cancer cells. Pluvicto is a
Pluvicto (prescribing information). Novartis AG; 2024. Accessed J. Palliative care. National
PLUVICTO safely and effectively. See full prescribing information for PLUVICTO. PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) injection, for intravenous use Initial U.S. Approval: INDICATIONS AND USAGE-PLUVICTO is a radioligand therapeutic agent indicated for the treatment of
What this means for patients: Today, a new treatment known as 177lutetium-PSMA-617 (Lu-PSMA; trade name Pluvicto) was approved by the FDA
The drug's called Pluvicto and it was approved in early 2024 for PMSA prostate cancer. radiotherapy cancersucks prostatecancerfighter
Comments
Edit: That's what is done...